GlassScriptPhysician profile
Martin B Engelhardt
NPI 1639178023
$2,487.50
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $313 · 2021: $846 · 2022: $406.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $661.28 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $384.83 | 2019-2022 | |
| Glaxosmithkline, LLC. | $231.15 | 2019-2022 | |
| Stryker Corporation | $162.17 | 2021 | |
| Eisai INC. | $141.28 | 2021 | |
| Allergan, INC. | $121.60 | 2019-2020 | |
| Astellas Pharma US INC | $88.01 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.73 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $81.82 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $70.58 | 2019 | |
| Genentech USA, INC. | $60.71 | 2019-2021 | |
| Gilead Sciences, INC. | $51.79 | 2019 | |
| Edwards Lifesciences Corporation | $45.59 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $38.51 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.02 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.60 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $30.19 | 2022 | |
| Novo Nordisk INC | $27.45 | 2019 | |
| Genzyme Corporation | $23.11 | 2019 | |
| Avanir Pharmaceuticals, INC. | $21.86 | 2019 | |
| Amneal Pharmaceuticals LLC | $21.51 | 2022 | |
| Merck Sharp & Dohme LLC | $19.24 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.98 | 2021 | |
| Intercept Pharmaceuticals, INC. | $17.84 | 2020 | |
| Sanofi Pasteur INC. | $14.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Engelhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.